Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A Single Measure of Cancer Burden Combining Incidence with Mortality Rates for Worldwide Application

  • Kim, Jeong Lim (Department of Public Health, Graduate School, College of Medicine, Yonsei University) ;
  • Cho, Kyoung-Hee (Department of Public Health, Graduate School, College of Medicine, Yonsei University) ;
  • Park, Eun-Cheol (Department of Public Health, Graduate School, College of Medicine, Yonsei University) ;
  • Cho, Woo Hyun (Eulji University)
  • Published : 2014.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

We attempted to develop an indicator combining incidence with mortality rates (single measure of cancer burden, SMCB) and to compare the magnitudes of cancer burden by world region. The SMCB was used to measure the size of cancer burden summarizing the incidence and mortality. The incidence and mortality were divided in equivalent forms and were split. The criteria dividing the size of cancer burden were used as the maximum incidence and mortality by men and women according to the world database, and the value corresponding to 10% of each maximum was set as the cut-off value. In SMCB, the size of cancer burden was highest for men with lung cancer (SMCB=18) and for women with breast cancer (SMCB=14) in MDR (more developed regions) compared to the size of burden in LDR (lower developed regions) (lung, SMCB=11, breast, SMCB=8). For men, the size of cancer burden by region was highest in EURO (SMCB=18, lung), followed by WPRO (SMCB=16, lung), PAHO (SMCB=14, prostate), AFRO (SMCB=8, prostate) and SEARO (SMCB=7, lung). Moreover, for women, the size of cancer burden was greatest in EURO (SMCB=14, breast), followed by PAHO (SMCB=13, breast), AFRO (SMCB=11, cervix uteri), EMRO (SMCB=9, breast) or SEARO (SMCB=8, cervix uteri) and WPRO (SMCB=7, lung). The summary indicator will help to provide a priority setting for reducing cancer burden in health policy.

Keywords

References

  1. Anand S, Hanson K (1997). Disability-adjusted life years: a critical review. J Health Econ, 16, 685-702. https://doi.org/10.1016/S0167-6296(97)00005-2
  2. Barker C, Green A (1996). Opening the debate on DALYs (disability-adjusted life years). Health policy plann, 11, 179-83. https://doi.org/10.1093/heapol/11.2.179
  3. Bray F, Jemal A, Grey N, et al (2012). Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol, 13, 790-801. https://doi.org/10.1016/S1470-2045(12)70211-5
  4. Bray F, MAller B (2006). Predicting the future burden of cancer. Nat Rev Cancer, 6, 63-74. https://doi.org/10.1038/nrc1781
  5. Bray F, Ren JS, Masuyer E, Ferlay J (2013). Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer, 132, 1133-45. https://doi.org/10.1002/ijc.27711
  6. Cho KH, Park S, Lee KS, et al (2013). A single measure of cancer burden in Korea from 1999 to 2010. Asian Pac J Cancer Prev, 14, 5249-55 https://doi.org/10.7314/APJCP.2013.14.9.5249
  7. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  8. Gold MR, Stevenson D, Fryback DG. (2002). HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Pub Health, 23, 115-34. https://doi.org/10.1146/annurev.publhealth.23.100901.140513
  9. Hakama M, Hakulinen T, Teppo L, Saxen E (1975). Incidence, mortality or prevalence as indicators of the cancer problem. CA-Cancer J Clin, 36, 2227-31.
  10. Health people 2010 Toolkit. A field guide to health planning. (2002). Public Health Foundation, 67-9.
  11. Ismail SI, Soubani M, Nimri JM, Al-Zeer AH (2013). Cancer incidence in Jordan from 1996 to 2009-A comprehensive study. Asian Pac J Cancer Prev, 14, 3527-34. https://doi.org/10.7314/APJCP.2013.14.6.3527
  12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA-Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  13. Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidem Biomar, 19, 1893-907. https://doi.org/10.1158/1055-9965.EPI-10-0437
  14. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA-Cancer J Clin, 58, 71-96. https://doi.org/10.3322/CA.2007.0010
  15. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50. https://doi.org/10.1200/JCO.2005.05.2308
  16. Kimman M, Norman R, Jan S, et al (2012). The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. https://doi.org/10.7314/APJCP.2012.13.2.411
  17. McCracken M, Olsen M, Chen MS, et al (2007). Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin, 57, 190-205. https://doi.org/10.3322/canjclin.57.4.190
  18. Mont D (2007). Measuring health and disability. Lancet, 369, 1658-63. https://doi.org/10.1016/S0140-6736(07)60752-1
  19. Neevan DR, Dsouza, NS Murthy, RY Aras (2013). Projection of cancer incident cases for India-till 2026. Asian Pac J Cancer Prev, 14, 4379-86. https://doi.org/10.7314/APJCP.2013.14.7.4379
  20. Ollberding NJ, Nomura AM, Wilkens LR, et al (2011). Racial/ ethnic differences in colorectal cancer risk: The multiethnic cohort study. Int J Cancer, 129, 1899-906. https://doi.org/10.1002/ijc.25822
  21. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43. https://doi.org/10.1016/S1470-2045(01)00486-7
  22. Parkin DM, Fernandez LM (2006). Use of statistics to assess the global burden of breast cancer. Breast J, 12 Suppl 1, S70-80. https://doi.org/10.1111/j.1075-122X.2006.00205.x
  23. Parkin DM, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6. https://doi.org/10.1002/ijc.1440
  24. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  25. Sant M, Francisci S, Capocaccia R, et al (2006). Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer, 119, 2417-22. https://doi.org/10.1002/ijc.22160
  26. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  27. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  28. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet, 24, 1840-50.
  29. Thun MJ, DeLancey JO, Center MM, et al (2010). The global burden of cancer: priorities for prevention. Carcinogenesis, 31, 100-10. https://doi.org/10.1093/carcin/bgp263
  30. Vainio H (2002). Social responsibility in cancer prevention research: IARC as a 'Global Science Force'. Asian Pac J Cancer Prev, 3, 267-72.
  31. Woolf SH, Stange KC (2006). A sense of priorities for the healthcare commons. Am J Prev Med, 31, 99-102.
  32. WHO (2002). Bull WHO, 80, 644-52.
  33. WHO. International Agency for Research on Cancer (IARC). http://globocan.iarc.fr/.
  34. WHO (2001). National burden of disease studies: a practical guide. 2nd ed. (2001). 9-15.
  35. WHO (2004). The Global Burden of Disease: 2004 update. (2008).

Cited by

  1. Randomized Control Study of Nedaplatin or Cisplatin Concomitant with Other Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.731
  2. In Vitro and in Vivo Antitumor Evaluation of Berbamine for Lung Cancer Treatment vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1767
  3. Lymphocyte Subgroups and their Surface Receptors NKG2D and NKG2A in Patients with Non-small Cell Lung Cancer vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2685
  4. RETRACTED ARTICLE: Down-regulated microRNA-124 expression as predictive biomarker and its prognostic significance with clinicopathological features in breast cancer patients vol.10, pp.1, 2015, https://doi.org/10.1186/s13000-015-0391-0
  5. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0135704
  6. Description of Deaths on Easter Island, 2000-2012 Period vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10091
  7. Expression of Tumor Necrosis Factor Receptor-associated Factor 6 in Lung Cancer Tissues vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10591
  8. Years of Potential Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Iran vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1845
  9. vol.9, pp.1179-5549, 2015, https://doi.org/10.4137/CMO.S22456
  10. WNT2 Promotes Cervical Carcinoma Metastasis and Induction of Epithelial-Mesenchymal Transition vol.11, pp.8, 2016, https://doi.org/10.1371/journal.pone.0160414
  11. Influence of Genotype and Haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the Incidence of Breast Cancer - a Case-Control Study in Jordan vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.261
  12. Ranking composite Cancer Burden Indices for geographic regions: point and interval estimates vol.29, pp.2, 2018, https://doi.org/10.1007/s10552-018-1000-9